Clinical Trials Logo

Gyrate Atrophy clinical trials

View clinical trials related to Gyrate Atrophy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05312736 Recruiting - Gyrate Atrophy Clinical Trials

Gyrate Atrophy Ocular and Systemic Study

GYROS
Start date: November 21, 2023
Phase:
Study type: Observational

The Gyrate Atrophy Ocular and Systemic Study characterizes the natural history of ornithine levels and retinal degeneration (RD) associated with disease-causing OAT variants in the presence of standard care dietary treatment regimens over 4 years. The research goal is to understand the impact of OAT mutations on plasma ornithine levels and retinal degeneration.

NCT ID: NCT02435940 Recruiting - Clinical trials for Retinitis Pigmentosa

Inherited Retinal Degenerative Disease Registry

MRTR
Start date: June 2014
Phase:
Study type: Observational [Patient Registry]

The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on their retinal disease and its progress; family history; genetic testing results; preventive measures; general health and interest in participation in research studies. The participants may also choose to ask their clinician to add clinical measurements and results at each clinical visit. Participants are urged to update the information regularly to create longitudinal records of their disease, from their own perspective, and their clinical progress. The overall goals of the Registry are: to better understand the diversity within the inherited retinal degenerative diseases; to understand the prevalence of the different diseases and gene variants; to assist in the establishment of genotype-phenotype relationships; to help understand the natural history of the diseases; to help accelerate research and development of clinical trials for treatments; and to provide a tool to investigators that can assist with recruitment for research studies and clinical trials.